electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance. For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com